Is Kiora Pharmaceuticals Stock a Good Investment?
Kiora Pharmaceuticals Investment Advice | KPRX |
- Examine Kiora Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Kiora Pharmaceuticals' leadership team and their track record. Good management can help Kiora Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Kiora Pharmaceuticals' business and its evolving consumer preferences.
- Compare Kiora Pharmaceuticals' performance and market position to its competitors. Analyze how Kiora Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Kiora Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Kiora Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Kiora Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Kiora Pharmaceuticals is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Kiora Pharmaceuticals Stock
Researching Kiora Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 48.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.32. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kiora Pharmaceuticals recorded earning per share (EPS) of 16.53. The entity last dividend was issued on the 30th of August 2019. The firm had 1:9 split on the 11th of June 2024.
To determine if Kiora Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Kiora Pharmaceuticals' research are outlined below:
| Kiora Pharmaceuticals generated a negative expected return over the last 90 days | |
| Kiora Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (12.51 M) with loss before overhead, payroll, taxes, and interest of (5.14 M). | |
| Kiora Pharmaceuticals currently holds about 2.43 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64. | |
| Latest headline from finance.yahoo.com: Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting |
Kiora Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Kiora Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Kiora Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kiora Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Kiora Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Kiora Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-25 | 2023-12-31 | -0.42 | -0.47 | -0.05 | 11 | ||
2023-08-08 | 2023-06-30 | -1.07 | -0.79 | 0.28 | 26 | ||
2024-08-09 | 2024-06-30 | -0.86 | -0.53 | 0.33 | 38 | ||
2022-03-02 | 2021-12-31 | -0.3 | -0.66 | -0.36 | 120 | ||
2019-11-07 | 2019-09-30 | -0.75 | -1.15 | -0.4 | 53 | ||
2024-05-10 | 2024-03-31 | -0.07 | 0.38 | 0.45 | 642 | ||
2023-11-09 | 2023-09-30 | -0.35 | -0.89 | -0.54 | 154 | ||
2023-05-09 | 2023-03-31 | -1.68 | -1.0 | 0.68 | 40 |
Know Kiora Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kiora Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kiora Pharmaceuticals backward and forwards among themselves. Kiora Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Kiora Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| U.s. Bancorp | 2024-12-31 | 8.0 | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 3.0 | |
| Ubs Group Ag | 2024-12-31 | 2.0 | |
| Activest Wealth Management | 2024-12-31 | 2.0 | |
| Sbi Securities Co Ltd | 2024-12-31 | 1.0 | |
| Susquehanna International Group, Llp | 2024-12-31 | 0.0 | |
| Sabby Management Llc | 2024-12-31 | 0.0 | |
| Citadel Advisors Llc | 2024-12-31 | 0.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 0.0 | |
| Aigh Capital Management, Llc | 2024-12-31 | 255.6 K | |
| Rosalind Advisors, Inc. | 2024-12-31 | 250.6 K |
Kiora Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.75 M.Market Cap |
|
Kiora Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.30) | (2.41) | |
| Return On Capital Employed | (1.20) | (1.14) | |
| Return On Assets | (0.82) | (0.86) | |
| Return On Equity | (2.36) | (2.24) |
Determining Kiora Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Kiora Pharmaceuticals is a good buy. For example, gross profit margin measures Kiora Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Kiora Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Kiora Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kiora Pharmaceuticals. Check Kiora Pharmaceuticals' Beneish M Score to see the likelihood of Kiora Pharmaceuticals' management manipulating its earnings.
Evaluate Kiora Pharmaceuticals' management efficiency
Kiora Pharmaceuticals has return on total asset (ROA) of 0.1296 % which means that it generated a profit of $0.1296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1369 %, meaning that it created $0.1369 on every $100 dollars invested by stockholders. Kiora Pharmaceuticals' management efficiency ratios could be used to measure how well Kiora Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.41 in 2025. Return On Capital Employed is likely to rise to -1.14 in 2025. At this time, Kiora Pharmaceuticals' Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 5.6 M in 2025, whereas Total Assets are likely to drop slightly above 11.7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.22 | 10.73 | |
| Tangible Book Value Per Share | (4.52) | (4.75) | |
| Enterprise Value Over EBITDA | (0.01) | (0.01) | |
| Price Book Value Ratio | 0.37 | 0.39 | |
| Enterprise Value Multiple | (0.01) | (0.01) | |
| Price Fair Value | 0.37 | 0.39 | |
| Enterprise Value | 208 K | 197.6 K |
The strategic initiatives led by Kiora Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta (0.29) |
Basic technical analysis of Kiora Stock
As of the 16th of March 2025, Kiora Pharmaceuticals secures the Standard Deviation of 4.1, mean deviation of 3.06, and Risk Adjusted Performance of 5.0E-4. Kiora Pharmaceuticals technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.Kiora Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kiora Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kiora Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kiora Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kiora Pharmaceuticals' Outstanding Corporate Bonds
Kiora Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kiora Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kiora bonds can be classified according to their maturity, which is the date when Kiora Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| KIRBY P 42 Corp BondUS497266AC03 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Kiora Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Kiora Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 5.0E-4 | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 3.06 | |||
| Coefficient Of Variation | (11,757) | |||
| Standard Deviation | 4.1 | |||
| Variance | 16.84 | |||
| Information Ratio | 0.0156 | |||
| Jensen Alpha | 0.0409 | |||
| Total Risk Alpha | 0.4691 | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 21.16 | |||
| Value At Risk | (5.65) | |||
| Potential Upside | 7.46 | |||
| Skewness | 0.5283 | |||
| Kurtosis | 0.4444 |
| Risk Adjusted Performance | 5.0E-4 | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 3.06 | |||
| Coefficient Of Variation | (11,757) | |||
| Standard Deviation | 4.1 | |||
| Variance | 16.84 | |||
| Information Ratio | 0.0156 | |||
| Jensen Alpha | 0.0409 | |||
| Total Risk Alpha | 0.4691 | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 21.16 | |||
| Value At Risk | (5.65) | |||
| Potential Upside | 7.46 | |||
| Skewness | 0.5283 | |||
| Kurtosis | 0.4444 |
Consider Kiora Pharmaceuticals' intraday indicators
Kiora Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kiora Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Kiora Pharmaceuticals Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 15th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Kiora Stock media impact
Far too much social signal, news, headlines, and media speculation about Kiora Pharmaceuticals that are available to investors today. That information is available publicly through Kiora media outlets and privately through word of mouth or via Kiora internal channels. However, regardless of the origin, that massive amount of Kiora data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kiora Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kiora Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kiora Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kiora Pharmaceuticals alpha.
Kiora Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Kiora Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kiora Pharmaceuticals Corporate Management
| MD MBA | Chief Officer | Profile | |
| Brian Strem | CEO and President | Profile | |
| Melissa Tosca | Ex Fin | Profile | |
| Stefan Sperl | Executive Operations | Profile | |
| MaryJane Rafii | Consultant | Profile | |
| Melissa CPA | Executive Finance | Profile |
Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.